MicroRNA-1296 Facilitates Proliferation, Migration and Invasion of Colorectal Cancer Cells By Targeting SFPQ

Youmao Tao1,#, Chong Ma1,#, Qihao Fan1, Yannan Wang1, Tao Han2,*, Caixia Sun1,*

1. Department of Gastrointestinal Colorectal and Anal Surgery
2. Department of Vascular Surgery, China-Japan Union Hospital of Jilin University, 126 Xiantai Street, Changchun, Jilin Province 130033, China

#Contributed equally

*Corresponding author: Caixia Sun, M.D., Ph.D., Department of Gastrointestinal Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, 126 Xiantai Street, Changchun 130033, China. Tel/Fax: +86-0431-89876666; Email: shenkexin1314@jlu.edu.cn and Tao Han, M.D, Ph.D, Department of Vascular Surgery, China-Japan Union Hospital of Jilin University, No.126 Xiantai Street, Changchun, Jilin Province 130033, China. Tel/Fax: +86-0431-84995222, Email: hqp_qld@163.com

© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Abstract

MicroRNAs (miRNAs) are involved in cancer genesis and progression via acting as tumor suppressors or oncogenes. Previous studies report that miR-1296 shows upregulation in both colorectal cancer (CRC) tissues and plasma samples. However, the accurate clinical significance of miR-1296 and its role in CRC have not been well investigated. The aim of the present study was to disclose the aberrant expression, clinical significance, and the relevant biological function of miR-1296 in CRC. We found a marked upregulation of miR-1296 expression in CRC tissues compared to tumor-adjacent tissues. MiR-1296 overexpression was detected in five CRC cell lines (HCT116, Caco2, HT29, SW620 and SW480). High miR-1296 level was remarkably correlated with tumor size (>5cm), lymph node metastasis and TNM stage (III+IV). Notably, high miR-1296 expression was identified as a predictive factor for poor prognosis of CRC patients by survival analysis. MiR-1296 knockdown inhibited proliferation, migration, invasion capacities of HCT116 and SW480 cells in vitro. Moreover, miR-1296 silencing restrained the growth of CRC cells in vivo. Splicing factor proline and glutamine rich (SFPQ), a novel RNA binding protein, was identified as a direct target gene of miR-1296 in CRC. Downregulation of SFPQ expression was inversely associated with miR-1296 expression in CRC tissues. The Cancer Genome Atlas (TCGA) data revealed the prognostic value of dysregulated SFPQ in CRC patients. Interestingly, our findings established that the oncogenic role of miR-1296 was at least partially mediated by SFPQ in CRC cells. Collectively, these data indicate that miR-1296 accelerates CRC progression possibly by targeting SFPQ and may serve as a potential predictive factor and therapeutic target for CRC.

Key words: Colorectal cancer; microRNA-1296; Tumor growth; Metastasis; SFPQ

Introduction

Colorectal cancer (CRC) is one of the leading cause for cancer-related death and ranks the third commonest cancer worldwide [1]. Surgery remains the most common curative therapy for CRC patients [2]. In spite of great advancement in the therapy regimen for CRC, such as systemic chemotherapy, radiotherapy, immunotherapy and targeted therapy, the post-surgical outcome of CRC patients is slightly improved due to the high rate of tumor recurrence and metastasis [3]. Accordingly, it is still urgently needed to uncover the molecular pathways underlying CRC progression and identify the novel biomarkers for predicting the post-surgical prognosis of CRC patients.

MicroRNAs (miRNAs) are a family of endogenous small non-coding RNAs (~22 nucleotides in length) that negatively regulate the expression of multiple genes either by inducing translational
repression or by causing the degradation of target messenger RNAs (mRNAs), via incompletely base-pairing to a complementary sequence in the 3’-untranslated region (3’-UTR) [4]. In some settings, miRNAs also interact with amino acid coding regions of their mRNA targets [5]. Increasing evidence show that dysregulated expression of miRNAs is involved in cancer progression and metastasis, and they may be the novel biomarkers and therapeutic targets for cancer treatment [6-8]. MiR-1296 is a newly identified cancer-related miRNA. For instance, miR-1296 is down-regulated in prostate cancer and inhibits cell cycle progression of cancer cells via targeting minichromosome maintenance 2 (MCM2) [9]. MiR-1296 reduces the expression of PIM2 and promotes apoptosis of HeLa cells [10]. MiR-1296 acts as a tumor suppressor by suppressing the expression of Cyclin D1 in triple-negative breast cancer [11]. Furthermore, down-regulation of miR-1296 facilitates the invasion and migration capacities of gastric cancer cells via targeting erb-b2 receptor tyrosine kinase 2 (ERBB2) [12]. Xu et al. report that miR-1296 restrains the metastatic behaviors of hepatocellular carcinoma cells by inhibiting SRPK1-mediated epithelial-to-mesenchymal transition (EMT) [13]. All these studies suggest a tumor suppressive role of miR-1296. However, miR-1296 is found to be a miRNA with prognostic significance in colon cancer and it is up-regulated in the group with disease recurrence [14]. Moreover, recent study reports that miR-1296 shows upregulation in both CRC tissues and plasma samples [15]. Thus, it is worth to investigate the clinical significance of miR-1296 and its role in CRC.

In this study, we attempted to figure out the potential of miR-1296 to function as a prognostic biomarker and provided a better understanding of its biological function in CRC progression.

Materials and methods

CRC patients and samples

A total of 80 CRC patients, who received surgery in China-Japan Union Hospital of Jilin University, were enrolled in this study. Ethical approval was obtained from the Research Ethics Committee of Jilin University. All the patients signed informed consent forms. None of them had received immunotherapy, radiotherapy or chemotherapy before surgery. All CRC tissues and their corresponding tumor-adjacent tissues were pathologically confirmed and conserved in liquid nitrogen. The clinicopathologic characteristics of patients were shown in Table 1.

Cell culture and transfection

Human CRC cell lines including HCT116, HT29, Caco-2, SW620, and SW480 and human intestinal epithelial cell line (HIEC) were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). All cells were cultured in standard growth medium at 37 °C with 5% CO2 in a humidified incubator as previously described [16]. MiR-1296 mimic (MC13743) and inhibitor (MIH13743) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Small interfering RNA (siRNA) that used to down-regulate splicing factor proline and glutamine rich (SFPQ) was purchased from GenePharma (Shanghai, China). Lipofectamine 3000 (Invitrogen, USA) was employed to perform transfection according to the manufacturer’s protocol. The SFPQ siRNA targeting sequence was listed as follow: 5’-GACGACAGGAAUUAAGGT-3’.

Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)

Total RNA of CRC cells and tissues was extracted using TRIzol reagent according to the manufacturer’s protocol (Invitrogen, Carlsbad, CA, USA). Total RNA (1 µg) was reversely transcribed into cDNA using a PrimeScript RT reagent kit (Takara, Dalian, China) and a TaqMan miRNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA). qRT-PCR was carried out in the Applied Biosystems 7500 Sequence Detection system using a miRNA-specific TaqMan miRNA Assay Kit (Applied Biosystems) and a SYBR Premix Ex Taq™ Kit (Takara, Shiga, Japan) with the following primers: miR-1296-5p (forward primer: 5′-TTG TTA GGG CCC TGG CTC -3′; reserve primer: 5′-GTG CAG GGT CCG AGG T-3′), SFPQ (forward primer: 5′-ATG TCT CGG GAT CGG TTC CGG A-3′; reserve primer: 5′-CCA ACA AAC AAC CGA CAT GCC TG-3′), U6 (forward primer: 5′-CGC TTC GGC AGC ACA TAT AC-3′; reverse primer: 5′-CAG GGG CGG AGC TAA TCT T-3′), GAPDH (forward primer: 5′-TGC ACC ACC AAC TGC TTA GC-3′; reverse primer: 5′-GCC ATG GAC TGT GGT CAT GAG-3′). The relative expression of miR-1296 and SFPQ mRNA were normalized to U6 small nuclear RNA and GAPDH, respectively, using 2^(-△△Ct) method.

Immunoblotting analysis

The protocol for Western blotting was described previously [17]. Briefly, CRC cells were lysed with RIPA buffer (Beyotime, Haimen, China) on ice. The protein concentration was measured by a Bradford Protein Assay Kit (Beyotime). The protein samples were separated by SDS-PAGE and electro-transferred onto a PVDF membrane. The membranes were blocked with 5% non-fat milk and then were incubated with SFPQ primary antibody (ab177149, Abcam, Cambridge, MA, USA) and GAPDH primary antibody (sc-47724, Santa Cruz Biotechnology, Santa
Cruz, CA, USA) at 4 °C overnight. The second day, the membranes were washed with TBST and incubated with HRP-labeled secondary antibodies (#7074 and 7076, Cell Signaling Technology, Beverly, MA, USA) for 2 hours. The signals were detected with an HRP chemiluminescent kit (Thermo Fisher Scientific, Waltham, MA, USA) and semi-quantified by ImageJ software (1.46; National Institutes of Health, Bethesda, MD, USA).

Proliferation assay

The measurement of cell proliferation was carried out by using Cell Counting Kit-8 (CCK-8; Beyotime, Shanghai, China) assay. CRC cells were plated in a 96-well plate in triplicate with 5×10³ cells/well. Then CCK8 solution was added to the well and incubated for 2 hours at 37°C. The absorbance at 490nm was evaluated by VICTOR3™ Multilabel Plate Reader (PerkinElmer Inc., Foster City, CA, USA). For colony formation assay, CRC cells (1×10³ cells/well) were plated in a 6-well plate and cultured for 2 weeks. The cell colonies were fixed with methanol and stained with crystal violet. The number of cell colonies were counted by using ImageQuant TL software (GE, USA).

Cell migration and invasion assay

The cell motility capacities were determined using a wound healing assay and a transwell chamber assay respectively, according to standard methods described before [18]. SW480 cells with miR-1296 overexpression were treated with mitomycin C (10 μg/ml, Sigma-Aldrich, St. Louis, MO, USA) for 2 h prior to the wound healing and transwell assay.

In vivo nude mice tumorigenesis

1×10⁶ SW480 cells with and without miR-1296 knockdown were injected subcutaneously into BALB/c female nude mice (n=5 for each group). Tumor size was measured each 4 days after implantation. Three weeks later, the mice were sacrificed under anesthesia for harvesting xenograft tissues. The tumor tissues were fixed in 10% formalin and then embedded in paraffin. Immunohistochemical staining was employed for detection of Ki-67 (#9449, Cell Signaling Technology) as previously described [16]. All animal experiments were approved by the Research Ethics Committee of Jilin University.

Luciferase reporter assay

The 3’UTR of SFPQ containing the putative binding region of miR-1296-5p was amplified from human genomic DNA. Then the sequence was cloned into pGL3 luciferase reporter vector (Promega, Madison, WI, USA). The potential binding sites for miR-1296-5p were mutated by the Quick-change site-directed mutagenesis kit (Agilent Technologies, Santa Clara, CA, USA). The wild type (wt) SFPQ 3’UTR vector or mutant (mt) SFPQ 3’UTR vector and miR-1296 mimic or inhibitor were co-transfected into HCT116 cells by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The luciferase activity was measured using Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA) under luminometer (Berthold Detection System, Pforzheim, Germany), and luciferase activity was normalized to Renilla activity.

Statistical analysis

All data were shown as mean ± standard deviation (SD) and analyzed by using GraphPad Prism software version 5.0 (San Diego, CA, USA). Statistical analysis was calculated by Chi-squared test, Student’s t-test, ANOVA, Spearman’s correlation analysis, Kaplan-Meier method and Log-rank test. P-value < 0.05 was considered as statistical significance. Each experiment was repeated three times.

Results

MiR-1296 expression is up-regulated in CRC and predicts poor prognosis

MiR-1296 expression profiles were evaluated in 80 paired CRC and tumor-adjacent tissues by qRT-PCR. Our data revealed that miR-1296 expression was up-regulated in CRC tissues compared to tumor-adjacent tissues (P=0.0002, Figure 1A). The expression difference of miR-1296 between five CRC cell lines (HCT116, Caco2, HT29, SW620 and SW480) and human intestinal epithelial cell line (HIEC) was further disclosed. All CRC cell lines showed a significant high expression of miR-1296 compared to HIEC cells (P<0.05, respectively, Figure 1B). Next, we determined the correlation between miR-1296 expression in tumor tissues and clinicopathological features of CRC patients. Different subgroups (low/high miR-1296 expression) were divided according to the median expression of miR-1296 in the cohort. As shown in Table 1, high miR-1296 expression in CRC tissues was positively associated with tumor size (>5 cm; P=0.043), lymph node metastasis (P=0.036) and TNM stage (III+IV; P=0.011), suggesting a correlation between miR-1296 overexpression and malignant behaviors of CRC. Kaplan-Meier method and the log-rank test were used to determine the role of miR-1296 expression in the post-surgical prognosis of CRC patients. We found that CRC patients with higher miR-1296 expression in tumor tissues suffered from the
unfavorable post-surgical survival than those with lower miR-1296 expression (P=0.0352, Figure 1C). Thus, miR-1296 is a potential effective predictive factor for the survival of CRC patients.

Table 1. The correlation between clinicopathological features and miR-1296 expression in colorectal cancer

| Features             | n     | miR-1296 expression | P     |
|----------------------|-------|---------------------|-------|
|                      |       | High (n=40)         | Low (n=40) |
| Age (years)          |       |                     |       |
| <60                  | 37    | 16                  | 21    | 0.262 |
| ≥60                  | 43    | 24                  | 19    | 0.361 |
| Gender               |       |                     |       |
| Male                 | 48    | 22                  | 26    |       |
| Female               | 32    | 18                  | 14    |       |
| Differentiation      |       |                     |       |
| Well/Moderately-differentiated | 56    | 24                  | 32    | 0.051 |
| Poorly-differentiated | 24    | 16                  | 8     |       |
| Size (cm)            |       |                     |       |
| <5                   | 45    | 18                  | 27    | 0.043 |
| ≥5                   | 35    | 22                  | 13    |       |
| Invasion depth       |       |                     |       |
| T1+T2                | 27    | 10                  | 17    | 0.098 |
| T3+T4                | 53    | 30                  | 23    |       |
| Lymph node metastasis|      |                     |       |
| Without              | 51    | 21                  | 30    | 0.036 |
| With                 | 29    | 19                  | 10    |       |
| TNM stage            |       |                     |       |
| I+II                 | 51    | 20                  | 31    | 0.011 |
| III+IV               | 29    | 20                  | 9     |       |

TNM: tumor-node-metastasis. * Statistically significant.

MiR-1296 knockdown restrains proliferation, migration and invasion of CRC cells

The qRT-PCR analysis confirmed that transfection of miR-1296 inhibitor resulted in miR-1296 knockdown in HCT116 and SW480 cells (P<0.05, respectively, Figure 2A). CCK8 and colony formation assays indicated that miR-1296 knockdown apparently suppressed proliferation of both HCT116 and SW480 cells (P<0.05, respectively, Figure 2B and 2C). Scratching wound healing assay also displayed that miR-1296 silencing markedly inhibited CRC cell migration (P<0.05, respectively, Figure 3A). Additionally, down-regulating miR-1296 expression led to decrease of invasion ability in both HCT116 and SW480 cells (P<0.05, respectively, Figure 3B). To distinguish cell migration and invasion from proliferation, SW480 cells with miR-1296 overexpression were treated with a proliferation blocker mitomycin C (10 µg/ml) for 2 h prior to the wound healing and transwell assay. Our data revealed that miR-1296 overexpression really promoted cell migration and invasion in SW480 cells (P<0.05, respectively, Figure S1).

MiR-1296 knockdown prohibits CRC growth in vivo

To further substantiate the action of miR-1296 on tumorigenicity in vivo, we carried out the CRC xenograft experiments in a nude mouse model using SW480 cells with or without miR-1296 knockdown. As shown in Figure 4A, the volumes of CRC xenografts in mice inoculated with miR-1296 knockdown SW480 cells were remarkably smaller as compared with controls (P<0.05). Moreover, IHC staining of Ki67 revealed that MiR-1296 knockdown suppressed the growth of CRC cells in vivo (P<0.05, Figure 4B). Xenograft tumor tissues arising from miR-1296 knockdown group showed a significant lower miR-1296 expression compared to control group (P<0.05, Figure S2). Collectively, these results indicate that miR-1296 plays a critical role in CRC cell growth in vivo.

SFPQ is a direct target of miR-1296 in CRC cells

Next, the candidate target genes of miR-1296 were predicted using TargetScan (http://www.targetscan.org) and miRanda (microRNA.org) online databases. We found that the 3’-UTR of SFPQ mRNA contained the complementary sequence of miR-1296 according to public available database analysis (Figure 5A). Thus, SFPQ was selected for further experimental validation. Enforced expression of miR-1296 led to decreased expression of SFPQ in HCT116 cells (P<0.05, Figure 5B). Moreover,
knockdown of miR-1296 significantly increased SFPQ expression in HCT116 cells (P<0.05, Figure 5B). Notably, miR-1296 restoration prominently reduced while miR-1296 silencing increased the fluorescence intensity of cells transfected with wt 3’UTR of SFPQ (P<0.05, respectively, Figure 5C). While, the fluorescence intensity of HCT116 cells had no significant variation after being transfected with miR-1296 mimic or inhibitor in the mutant group (Figure 5C). The expression of SFPQ mRNA was determined to be down-regulated in CRC tissues compared to tumor-adjacent tissues (P<0.0001, Figure 5D). An inverse correlation between miR-1296 and SFPQ mRNA expression was detected in CRC tissues (r=-0.6469, P<0.0001, Figure 5E). Different subgroups (low/high SFPQ expression) were divided according to the median expression of SFPQ in the cohort of CRC patients from TCGA database. CRC patients with low SFPQ level had a significant shorter overall survival compared to those with high SFPQ level (P=0.0143, Figure 5F). Thus, miR-1296 is a direct negative regulator of SFPQ in CRC.

**SFPQ is essential for miR-1296 associated phenotypes in CRC cells**

Since SFPQ was a direct target of miR-1296, we then carried out rescue experiments to confirm that SFPQ was required for miR-1296-associated phenotypes in CRC cells. SW480 cells with miR-1296 knockdown were transfected with a specific siRNA targeting SFPQ (P<0.05, Figure 6A), and the cell proliferation and metastasis abilities were measured. We found that silencing SFPQ expression led to an obvious increased proliferation rate in SW480 cells with miR-1296 knockdown (P<0.05, respectively, Figure 6B and 6C). Similarly, SFPQ knockdown dramatically enhanced the migration and invasion capacities of SW480 cells with miR-1296 knockdown, as determined by wound healing and transwell invasion assays, respectively (P<0.05, respectively, Figure 6D and 6E). These data confirm that SFPQ is a downstream effector of miR-1296 in CRC cells.

**Discussion**

MiR-1296 has been reported to have a close correlation with human cancers, such as breast cancer, hepatocellular carcinoma, gastric cancer and prostate cancer [9, 11-13]. MiR-1296 usually functions as a tumor suppressor by directly targeting oncogenic genes [9, 11-13]. However, recent studies report that miR-1296 is over-expressed in both CRC tissues and plasma samples, and its up-regulation is correlated with colon cancer recurrence [14, 15]. Thus, the expression and role of miR-1296 in human cancer is a
controversial topic. In the present study, we found that miR-1296 expression level was higher in CRC tissues than that in tumor adjacent tissues, indicating that miR-1296 may serve as an oncogenic miRNA in CRC progression. The observation was also confirmed in CRC cell lines compared to HIEC cell line. Notably, CRC patients with high miR-1296 level had larger tumor size, more lymph node metastasis, advanced TNM tumor stage and shorter survival. Based on these observations, we further carried out the gain- and loss-of-function analyses to clarify the biological functions of miR-1296 in terms of CRC cell proliferation, migration and invasion. The results indicated that miR-1296 knockdown suppresses CRC cell growth and metastasis in vitro and in vivo.

Figure 3. MiR-1296 knockdown inhibits migration and invasion of CRC cells. HCT116 and SW480 cells that were transfected with miR-1296 inhibitor and control inhibitor, respectively. (A) Wound healing assays indicated that miR-1296 knockdown suppressed the migration of both HCT116 and SW480 cells. n=three independent experiments, *P<0.05 by Student’s t-test. (B) The number of invaded cells was significantly reduced after miR-1296 knockdown in both HCT116 and SW480 cells. n= five fields of three independent experiments, *P<0.05 by Student’s t-test.
Figure 4. MiR-1296 knockdown restrains SW480 cell growth in vivo. SW480 cells with or without miR-1296 knockdown were implanted into nude mice via subcutaneous injection. (A) Tumor growth curves revealed that CRC xenografts arising from miR-1296 knockdown group grew slower than those arising from control group. n=5, *P<0.05 by two-way ANOVA. Scale bar: 1 cm. (B) The percentage of Ki-67 staining cancer cells was significantly reduced in miR-1296 knockdown group compared to control group. n=5, *P<0.05 by Student’s t-test.

Figure 5. MiR-1296 directly regulates SFPQ expression in CRC cells. (A) The complementary sequences of miR-1296 were discovered in 3’UTR of SFPQ mRNA using TargetScan (http://www.targetscan.org) and miRanda (miRNA.org). The mutagenesis was performed in the complementary sites for the seed region of miR-1296 (wt, wild type; mt, mutant type). (B) HCT116 cells were transfected with miR-1296 mimic and miR-1296 inhibitor, respectively. qRT-PCR results indicated that miR-1296 overexpression reduced while miR-1296 silencing increased the expression of SFPQ. n=three independent experiments, *P<0.05 by Student’s t-test. (C) MiR-1296 inversely modulated the luciferase activity of plasmids that carried wt 3’UTR of SFPQ rather than mt 3’UTR of SFPQ. n=three independent experiments, *P<0.05 by Student’s t-test. (D) Down-regulation of SFPQ mRNA was detected in CRC tissues compared to tumor-adjacent tissues. P<0.05 by Student’s t-test. (E) MiR-1296 was negatively correlated with SFPQ mRNA expression in CRC tissues. n=80, P<0.05 by Spearman’s correlation test. (F) Different subgroups (low/high SFPQ expression) were divided according to the median expression of SFPQ in the cohort of CRC patients from TCGA database. CRC patients with low SFPQ level had a significant shorter overall survival compared to those with high SFPQ level. P<0.05 by Log-rank test.
To understand the molecular mechanisms of miR-1296 as an oncogene in CRC, we searched for putative target genes of miR-1296 by using public available database and SFPQ was selected out for subsequent research in this study. SFPQ was identified as a direct target of miR-1296 by using luciferase reporter assay. Furthermore, miR-1296 inversely modulated SFPQ abundance in CRC cells and negatively correlated with SFPQ mRNA expression in CRC tissues. Survival analysis of CRC patients from TCGA database revealed that CRC patients with low SFPQ level had a significant shorter overall survival compared to those with high SFPQ level. Torres et al. investigate the prognostic value of SFPQ in CRC patients using the GSE17538 and GSE39582 data set and find a consistent result with us.
SFPQ, containing an RNA-binding domain and a DNA-binding domain, is implicated in multiple cellular functions including DNA repair, pre-mRNA splicing and transcription regulation [20, 21]. Previous studies have recognized SFPQ as a tumor-suppressor protein [22, 23]. SFPQ regulates the oncogenic role of polypyrimidine tract binding protein 2 (PTBP2) by forming a complex with PTBP2 [24]. Long non-coding RNA (lncRNA) metastasis associated with lung adenocarcinoma transcript-1 (MALAT1) contributes to the growth and metastasis of CRC by binding to SFPQ and subsequently releasing proto-oncogene PTBP2 [25]. SFPQ knockdown prominently facilitates the proliferation and migration ability of CRC cells, and it is essential for the oncogenic role of MALAT1 [25]. Furthermore, lncRNA gastric adenocarcinoma predictive long intergenic noncoding (GAPLINC) binds to SFPQ and abrogates the pro-metastatic role of GAPLINC in CRC cells [26]. Next, we proceeded to address the biological significance of the miR-1296-SFPQ axis in the regulation of CRC cell phenotypes. SW480 cells with miR-1296 knockdown were transfected with a specific siRNA targeting SFPQ and then examined for cell proliferation, migration and invasion. Silencing of SFPQ significantly enhanced both proliferation and metastasis abilities of SW480 cells with miR-1296 knockdown, suggesting that miR-1296 exerts its function, at least in part, through regulating SFPQ expression.

In summary, we demonstrate that upregulation of miR-1296 acts as a promising indicator for poor prognosis of CRC patients. Moreover, miR-1296 facilitates CRC cell proliferation and metastasis, at least partially, by regulating SFPQ expression. These findings reveal a new mechanism by which miR-1296 may act as a candidate oncogene in CRC. Our data suggest that miR-1296 may have great potential in controlling tumorigenesis and metastasis, and further confirm that miR-1296 is a promising target for CRC prevention and therapy.

Abbreviations

CRC: colorectal cancer; miRNAs: microRNAs; 3’-UTR: 3’-untranslated region; MCM2: minichromosome maintenance 2; ERBB2: erb-b2 receptor tyrosine kinase 2; EMT: epithelial-to-mesenchymal transition; SFPQ: Splicing factor proline and glutamine rich; qRT-PCR: quantitative reverse transcription-polymerase chain reaction; CCK-8: Cell Counting Kit-8; PTBP2: polypyrimidine tract binding protein 2; LncRNA: long non-coding RNA; MALAT1: metastasis associated with lung adenocarcinoma transcript-1; GAPLINC: gastric adenocarcinoma predictive long intergenic noncoding; TCGA: The Cancer Genome Atlas; GEO: Gene Expression Omnibus.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Siegel RL, Miller KD, Jemal A. Cancer Statistics. 2017. CA Cancer J Clin. 2017; 67:7-30.
2. Li L, Ma BB. Colorectal cancer in Chinese patients: current and emerging treatment options. Oncol Targets Ther. 2014; 7:1817-28.
3. Stanley AR, Nan H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet. 2016; 7:105-14.
4. Dou C, Liu Z, Xu M, Jia Y, Wang Y, Li Q, et al. miR-187-3p inhibits the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting S100A4. Cancer Lett. 2016; 381:380-9.
5. Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol. 2012; 6:590-610.
6. Luo H, Wang Y, Wang L, Yao B, Li Q, Wang C, et al. MiR-324-3p promotes tumor growth through targeting DACT1 and activation of Wnt-beta-catenin pathway in hepatocellular carcinoma. Oncotarget. 2017; 8:65067-98.
7. Tao J, Liu Z, Wang Y, Wang L, Yao B, Li Q, et al. MiR-542-3p inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting UBE3C. Biomed Pharmacother. 2017; 93: 420-8.
8. Tao Y, Song Y, Han T, Wang C, Zhao T, Gu Y. miR-205 regulation of IFT1 has an oncogenic potential via promoting the migration and invasion of gastric cancer cells. Biomed Pharmacother. 2017; 96: 191-7.
9. Majid S, Dar AA, Saini S, Chen Y, Shahrvari Y, Liu J, et al. Regulation of minichromosome maintenance gene family by microRNA-1296 and genistein in prostate cancer. Cancer Res. 2010; 70: 2899-8019.
10. Liu Z, He W, Gao J, Luo J, Huang X, Gao C. Computational prediction and experimental validation of a novel synthesized pan-PIM inhibitor PI003 and its apoptosis-inducing mechanisms in cervical cancer. Oncotarget. 2015; 6: 8019-35.
11. Phan B, Majid S, Ursu S, de Semir D, Nosrati M, Bezrookove V, et al. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer. Oncotarget. 2016; 7: 19519-30.
12. Shan X, Wen W, Zhu D, Yan T, Cheng W, Huang Z, et al. miR-1296-5p Inhibits the Migration and Invasion of Gastric Cancer Cells by Repressing ERBB2 Expression. PLoS One. 2017; 12: e0172098.
13. Xu Q, Liu X, Liu Z, Zhou Z, Wang Y, Tu J, et al. MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway. Mol Cancer. 2017; 16: 103.
14. Bobowicz M, Skrzypski M, Czapienski P, Maciejewska A, Jankowski M, et al. Prognostic value of 5-microRNA based signature in T2-T3N0 colon cancer. Clin Transl Oncol. 2016; 33: 765-73.
15. Nagy ZB, Bartak BK, Kalmar A, Galamb O, Wichmann B, Dank M, et al. Comparison of Circulating miRNAs Expression Alterations in Matched Tissue and Plasma Samples During Colorectal Cancer Progression. Pathol Oncol Res. 2017.
16. Tao Y, Han T, Zhang T, Sun C. Sulfatase-2 promotes the growth and metastasis of colorectal cancer by activating Akt and Erk1/2 pathways. Biomed Pharmacother. 2017; 89: 1370-7.
17. Tao Y, Sun C, Zhang T, Song Y. SMURF1 promotes the proliferation, migration and invasion of gastric cancer cells. Oncol Rep. 2017; 38: 1806-14.
18. Tao Y, Yang S, Wu Y, Fang X, Wang Y, Song Y, et al. MicroRNA-216a inhibits the metastasis of gastric cancer cells by targeting AK2/STAT3-mediated EMT process. Oncotarget. 2017; 8: 70200.
19. Torres S, Garcia-Palermo I, Marín-Vicente C, Bartolome RA, Calvino E, Fernandez-Acero MJ, et al. Proteomic Characterization of Splicing and Splicing Factors Associated with a Metastatic Phenotype in Colorectal Cancer. J Proteome Res. 2016; 15: 765-73.
20. Rosorina E, Ip JY, Calarco JA, Bakowski MA, Emili A, McCracken S, et al. Role for PSF in mediating transcriptional activator-dependent stimulation of pre-mRNA processing in vivo. Mol Cell Biol. 2005; 25: 6733-46.
21. Urban RJ, Bodenburg Y, Kurosky A, Wood TG, Gasic S. Polypyrimidine tract-binding protein-associated splicing factor is a negative regulator of transcriptional activity of the porcine pS50c insulin-like growth factor response element. Mol Endocrinol. 2000; 14: 774-92.
22. Wang G, Cui Y, Zhang G, Garen A, Song X. Regulation of proto-oncogene transcription, cell proliferation, and tumorigenesis in mice by PSF protein and a VL30 noncoding RNA. Proc Natl Acad Sci U S A. 2009; 106: 16794-8.
23. Song X, Sun Y, Garen A. Roles of PSF protein and VL30 RNA in reversible gene regulation. Proc Natl Acad Sci U S A. 2005; 102: 12189-93.
24. Meissner M, Dechat T, Gerner C, Grimm R, Foisner R, Sauermann G. Differential nuclear localization and nuclear matrix association of the splicing factors PSF and PTB. J Cell Biochem. 2000; 76: 559-66.
25. Ji Q, Zhang L, Liu X, Zhou L, Wang W, Han Z, et al. Long non-coding RNA MALAT1 promotes tumour growth and metastasis in colorectal cancer through binding to SFPQ and releasing oncogene PTBP2 from SFPQ/PTBP2 complex. Br J Cancer. 2014; 111: 736-48.
26. Yang P, Chen T, Xu Z, Zhu H, Wang J, He Z. Long non-coding RNA GAPLINC promotes invasion in colorectal cancer by targeting SNAI2 through binding with PSF and NONO. Oncotarget. 2016; 7: 42183-94.